<scp>AZP2006</scp> in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression
Jean‐Christophe Corvol(Centre National de la Recherche Scientifique), Luc Defebvre(Hôpital Roger Salengro), Olivier Defert(CHemProtect (Czechia)), Cecilia Estrella(CHemProtect (Czechia)), Mickaël Alexandre Obadia(Fondation Ophtalmologique Adolphe de Rothschild), David Devos(Université de Lille), Graziella Mangone(Sorbonne Université), Noëlle Callizot(L.Garde (United States)), Günter U. Höglinger(German Center for Neurodegenerative Diseases), Aurélien Blondel(CHemProtect (Czechia)), Louise‐Laure Mariani(Centre National de la Recherche Scientifique), Caroline Moreau(Hôpital Européen Georges-Pompidou), Artin Karapet(CHemProtect (Czechia)), Jean‐Philippe Brandel(Broad Institute), Sara Sambin(Université Paris-Est Créteil), Nicolas Carrière(Inserm), Marie Lebouteux(Fondation Ophtalmologique Adolphe de Rothschild), Philippe Verwaerde(CHemProtect (Czechia))
Cited by 0
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
|Movement Disorders|2022|788
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
|The Lancet Neurology|2024|499
Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy
|The American Journal of Human Genetics|2016|449